| Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy A Hochhaus, S Kreil, AS Corbin, P La Rosee, MC Müller, T Lahaye, ... Leukemia 16 (11), 2190-2196, 2002 | 1213 | 2002 |
| Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) B Hanfstein, MC Müller, R Hehlmann, P Erben, M Lauseker, A Fabarius, ... Leukemia 26 (9), 2096-2102, 2012 | 500 | 2012 |
| Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV A Fabarius, A Leitner, A Hochhaus, MC Müller, B Hanfstein, C Haferlach, ... Blood, The Journal of the American Society of Hematology 118 (26), 6760-6768, 2011 | 330 | 2011 |
| Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results … R Hehlmann, MC Müller, M Lauseker, B Hanfstein, A Fabarius, ... Journal of clinical oncology 32 (5), 415-423, 2014 | 323 | 2014 |
| Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV L Kalmanti, S Saußele, M Lauseker, MC Müller, CT Dietz, L Heinrich, ... Leukemia 29 (5), 1123-1132, 2015 | 291 | 2015 |
| Harmonization of molecular monitoring of CML therapy in Europe MC Müller, NCP Cross, P Erben, T Schenk, B Hanfstein, T Ernst, ... Leukemia 23 (11), 1957-1963, 2009 | 264 | 2009 |
| Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV S Saußele, MP Krauß, R Hehlmann, M Lauseker, U Proetel, L Kalmanti, ... Blood, The Journal of the American Society of Hematology 126 (1), 42-49, 2015 | 182 | 2015 |
| Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib B Hanfstein, V Shlyakhto, M Lauseker, R Hehlmann, S Saussele, C Dietz, ... Leukemia 28 (10), 1988-1992, 2014 | 160 | 2014 |
| Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib B Hanfstein, M Lauseker, R Hehlmann, S Saussele, P Erben, C Dietz, ... haematologica 99 (9), 1441, 2014 | 122 | 2014 |
| ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia T Ernst, J Hoffmann, P Erben, B Hanfstein, A Leitner, R Hehlmann, ... Haematologica 93 (9), 1389-1393, 2008 | 79 | 2008 |
| Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML A Fabarius, L Kalmanti, CT Dietz, M Lauseker, S Rinaldetti, C Haferlach, ... Annals of hematology 94, 2015-2024, 2015 | 78 | 2015 |
| Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV MB Miranda, M Lauseker, MP Kraus, U Proetel, B Hanfstein, A Fabarius, ... Leukemia 30 (6), 1255-1262, 2016 | 75 | 2016 |
| Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV L Kalmanti, S Saussele, M Lauseker, U Proetel, MC Müller, B Hanfstein, ... Annals of hematology 93, 71-80, 2014 | 69 | 2014 |
| KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer P Erben, P Ströbel, K Horisberger, J Popa, B Bohn, B Hanfstein, G Kähler, ... International Journal of Radiation Oncology* Biology* physics 81 (4), 1032-1038, 2011 | 68 | 2011 |
| Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy B Hanfstein, MC Müller, S Kreil, T Ernst, T Schenk, C Lorentz, ... haematologica 96 (3), 360, 2011 | 67 | 2011 |
| Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value A Hochhaus, MC Müller, J Radich, S Branford, HM Kantarjian, B Hanfstein, ... Leukemia 23 (9), 1628-1633, 2009 | 60 | 2009 |
| Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group E Lengfelder, B Hanfstein, C Haferlach, J Braess, U Krug, K Spiekermann, ... Annals of Hematology 92, 41-52, 2013 | 57 | 2013 |
| SAKK; German CML Study Group. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) B Hanfstein, MC Müller, R Hehlmann, P Erben, M Lauseker, A Fabarius, ... Leukemia 26 (9), 2096-2102, 2012 | 47 | 2012 |
| Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group. Impact of additional cytogenetic aberrations at diagnosis on prognosis of … A Fabarius, A Leitner, A Hochhaus, MC Müller, B Hanfstein, C Haferlach, ... Blood 118 (26), 6760-6768, 2011 | 45 | 2011 |
| Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase M Lauseker, B Hanfstein, C Haferlach, S Schnittger, M Pfirrmann, ... Journal of cancer research and clinical oncology 140, 1965-1969, 2014 | 37 | 2014 |
